A significant improvement in patients quality of life Long term therapeutic effect for 3 years after treatment New possibilities of therapy for inoperable patients Proven clinical efficacy

19
May 2016 EUROPEAN SOCIETY OF VASCULAR SURGEONS discussed the results of gene therapy developed by HSCI. 12
May 2015 Russian drug Neovasculgen increases growth of blood vessels in patients with lower limb ischemia 6
Apr 2015 Neovasculgen therapy results passed international expertise
23
Jan 2015 First gene therapy drug in EU to be marketed in Germany starting from 2015 11
Nov 2014 New gene therapy delivery system 4
Jul 2014 Development of Russian innovative drug for peripheral arterial disease is supported by the council of maryland biotech companies (USA)